ASP2151
ASP2151 is a pharmaceutical drug with 12 clinical trials. Historical success rate of 91.7%.
Success Metrics
Based on 11 completed trials
Phase Distribution
Phase Distribution
7
Early Stage
2
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
91.7%
11 of 12 finished
8.3%
1 ended early
0
trials recruiting
12
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Phase III Study of ASP2151 in Herpes Simplex Patients
Open-label Study of ASP2151 in Herpes Simplex Patients
Drug-Drug Interaction Study: ASP2151 and Montelukast
Drug-Drug Interaction Study: ASP2151 and Ritonavir
Drug-Drug Interaction Study: ASP2151 and Midazolam
Clinical Trials (12)
Phase III Study of ASP2151 in Herpes Simplex Patients
Open-label Study of ASP2151 in Herpes Simplex Patients
Drug-Drug Interaction Study: ASP2151 and Montelukast
Drug-Drug Interaction Study: ASP2151 and Ritonavir
Drug-Drug Interaction Study: ASP2151 and Midazolam
Drug-Drug Interaction Study: ASP2151 and Bupropion
Phase III Study of ASP2151 in Herpes Zoster Patients
Dose-finding Study of ASP2151 in Subjects With Herpes Zoster
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
Study to Evaluate the Safety and Pharmacokinetics of ASP2151 in Healthy Non-elderly and Elderly Subjects
Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food
Study Comparing the Safety of ASP2151 to Valacyclovir and Placebo in Healthy Volunteers
All 12 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 12